Leeward Investments LLC MA Trims Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Leeward Investments LLC MA trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 94,287 shares of the medical equipment provider's stock after selling 3,293 shares during the period. Leeward Investments LLC MA's holdings in Zimmer Biomet were worth $10,671,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Dodge & Cox raised its position in Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Zimmer Biomet by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after purchasing an additional 176,337 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Northern Trust Corp lifted its position in shares of Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after buying an additional 167,435 shares during the last quarter. Finally, Norges Bank acquired a new stake in Zimmer Biomet in the fourth quarter valued at about $216,223,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Price Performance

ZBH stock traded down $1.09 during mid-day trading on Monday, hitting $92.58. 1,994,496 shares of the stock were exchanged, compared to its average volume of 1,812,131. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The business has a fifty day moving average price of $94.04 and a 200 day moving average price of $101.73. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The stock has a market capitalization of $18.32 billion, a price-to-earnings ratio of 20.48, a PEG ratio of 2.17 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The firm had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the company posted $1.94 earnings per share. The company's revenue was up 1.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZBH. JMP Securities reduced their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Canaccord Genuity Group decreased their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Morgan Stanley cut their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Finally, The Goldman Sachs Group cut their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $111.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.